Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Accumulated Expenses (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Accumulated Expenses for 10 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses fell 64.61% to $1.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.6 million, a 64.61% decrease, with the full-year FY2024 number at $1.5 million, up 25.13% from a year prior.
  • Accumulated Expenses was $1.6 million for Q3 2025 at Rein Therapeutics, up from $640000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $4.8 million in Q1 2025 to a low of $12000.0 in Q3 2023.
  • A 5-year average of $1.8 million and a median of $1.2 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: tumbled 99.66% in 2023, then skyrocketed 38066.67% in 2024.
  • Rein Therapeutics' Accumulated Expenses stood at $3.2 million in 2021, then plummeted by 86.74% to $425000.0 in 2022, then skyrocketed by 177.18% to $1.2 million in 2023, then grew by 25.13% to $1.5 million in 2024, then rose by 9.97% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Accumulated Expenses are $1.6 million (Q3 2025), $640000.0 (Q2 2025), and $4.8 million (Q1 2025).